Emily Bodnar
Stock Analyst at H.C. Wainwright
(0.23)
# 4,712
Out of 5,162 analysts
701
Total ratings
30%
Success rate
-3.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Initiated Coverage: Buy | $10 | $0.9796 | +920.82% | 10 | Nov 2, 2026 | |
| NKTX Nkarta | Initiated Coverage: Buy | $14 → $12 | $1.12 | +971.43% | 33 | Nov 2, 2026 | |
| ARTV Artiva Biotherapeutics | Reiterated: Buy | $35 | $3.83 | +813.84% | 12 | Oct 1, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $45 | $15.78 | +185.17% | 22 | Sep 25, 2026 | |
| AGEN Agenus | Reiterated: Buy | $25 | $6.14 | +307.17% | 42 | Sep 21, 2026 | |
| GERN Geron | Reiterated: Hold | n/a | $0.913 | - | 15 | Sep 21, 2026 | |
| JSPR Jasper Therapeutics | Reiterated: Buy | $600 | $10.75 | +5,481.40% | 23 | Sep 21, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $44 | $18.34 | +139.91% | 3 | Sep 21, 2026 | |
| OLMA Olema Oncology | Reiterated: Buy | $36 | $7.15 | +403.50% | 48 | Sep 21, 2026 | |
| PPBT Purple Biotech | Reiterated: Buy | $17 | $1.53 | +1,011.11% | 21 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.74 | +302.30% | 28 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $78 | $64.88 | +20.22% | 15 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $16.36 | +156.72% | 12 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $44.46 | +28.21% | 6 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $2.28 | +1,259.65% | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $0.565 | +4,324.78% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $8.61 | +306.50% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.40 | +1,257.14% | 25 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.78 | +194.99% | 16 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $60 | $39.86 | +50.53% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.1686 | +2,865.60% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.91 | +243.64% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $55 | $28.76 | +91.24% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $10.69 | +386.44% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.75 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.79 | +330.11% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $66 | $47.40 | +39.24% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $3.67 | +390.46% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.000001 | n/a | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57.35 | $4.66 | n/a | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $1.26 | n/a | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.30 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.6282 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.2839 | n/a | 6 | May 22, 2024 |
Autolus Therapeutics
Nov 2, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $0.9796
Upside: +920.82%
Nkarta
Nov 2, 2026
Initiated Coverage: Buy
Price Target: $14 → $12
Current: $1.12
Upside: +971.43%
Artiva Biotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $35
Current: $3.83
Upside: +813.84%
Arcus Biosciences
Sep 25, 2026
Reiterated: Buy
Price Target: $45
Current: $15.78
Upside: +185.17%
Agenus
Sep 21, 2026
Reiterated: Buy
Price Target: $25
Current: $6.14
Upside: +307.17%
Geron
Sep 21, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.913
Upside: -
Jasper Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $600
Current: $10.75
Upside: +5,481.40%
Odyssey Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $44
Current: $18.34
Upside: +139.91%
Olema Oncology
Sep 21, 2026
Reiterated: Buy
Price Target: $36
Current: $7.15
Upside: +403.50%
Purple Biotech
Sep 21, 2026
Reiterated: Buy
Price Target: $17
Current: $1.53
Upside: +1,011.11%
Sep 21, 2026
Reiterated: Buy
Price Target: $7
Current: $1.74
Upside: +302.30%
Sep 21, 2026
Reiterated: Buy
Price Target: $78
Current: $64.88
Upside: +20.22%
Sep 21, 2026
Reiterated: Buy
Price Target: $42
Current: $16.36
Upside: +156.72%
Sep 3, 2026
Reiterated: Buy
Price Target: $57
Current: $44.46
Upside: +28.21%
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $2.28
Upside: +1,259.65%
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $0.565
Upside: +4,324.78%
Aug 14, 2026
Reiterated: Buy
Price Target: $35
Current: $8.61
Upside: +306.50%
Aug 13, 2026
Reiterated: Buy
Price Target: $19
Current: $1.40
Upside: +1,257.14%
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $6.78
Upside: +194.99%
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $39.86
Upside: +50.53%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.1686
Upside: +2,865.60%
Aug 6, 2026
Reiterated: Buy
Price Target: $10
Current: $2.91
Upside: +243.64%
Jul 30, 2026
Reiterated: Buy
Price Target: $52 → $55
Current: $28.76
Upside: +91.24%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $10.69
Upside: +386.44%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $1.75
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: $12
Current: $2.79
Upside: +330.11%
Mar 30, 2026
Reiterated: Buy
Price Target: $55 → $66
Current: $47.40
Upside: +39.24%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $3.67
Upside: +390.46%
Nov 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Oct 13, 2025
Reiterated: Buy
Price Target: $57.35
Current: $4.66
Upside: n/a
Sep 26, 2025
Reiterated: Buy
Price Target: $160
Current: $1.26
Upside: n/a
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $1.30
Upside: n/a
Mar 31, 2025
Reiterated: Buy
Price Target: $8
Current: $0.6282
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $0.2839
Upside: n/a